NANOVIBRONIX INC (NAOV)       0.3201  -0.02 (-5.27%)

0.3201  -0.02 (-5.27%)

US63008J1088 - Common Stock - After market: 0.32 0 (-0.03%)


Fundamental Rating

2

Taking everything into account, NAOV scores 2 out of 10 in our fundamental rating. NAOV was compared to 223 industry peers in the Health Care Equipment & Supplies industry. NAOV has a bad profitability rating. Also its financial health evaluation is rather negative. NAOV is quite expensive at the moment. It does show a decent growth rate.

Note: NAOV has only limited data available, so a full analysis was not possible, which makes the total rating unfair.




Profitability

Profitability Rating

0

The Piotroski-F score of NAOV is 2.00. This is a very weak score and indicates problems in health and profitability for NAOV.

VS Industry

Valuation

Valuation Rating

1

When comparing the current price to the book value of NAOV, we can conclude it is valued correctly. It is trading at 3.33 times its book value.
When comparing the price book ratio of NAOV to the average industry price book ratio of 2.90, NAOV is valued in line with its industry peers.

The Price/Earnings Ratio is negative for NAOV. In the last year negative earnings were reported.
VS Industry

Price/Book (3.33) VS Industry: 45% outperformed.

1,369.61
0.21

Growth

Growth Rating

5

NAOV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 58.42%, which is quite impressive.
The Revenue has grown by 61.77% in the past year. This is a very strong growth!

The Revenue has been growing by 49.10% on average over the past 5 years. This is a very strong growth!

PastFuture
5Y3Y1Y1Y2Y3Y5Y
EPSN/A N/A 58.42% N/A N/A N/A N/A
Revenue49.1% 74.32% 61.77% N/A N/A N/A N/A

Health

Health Rating

2

A Current Ratio of 2.91 indicates that NAOV has no problem at all paying its short term obligations.
NAOV has a Quick Ratio of 2.00. This indicates that NAOV is financially healthy and has no problem in meeting its short term obligations.
With a Debt to Equity ratio of 0.00, NAOV is doing better than the averages in the industry. The industry average is at 0.11.
Compared to an average industry Current Ratio of 3.69, NAOV is worse placed to pay its short term obligations than its industry peers.

When comparing the Quick Ratio of NAOV to the average industry Current Ratio of 2.91, NAOV is less able to pay its short term obligations than its industry peers.
Based on the Altman-Z score of -15.76, we must say that NAOV is in the distress zone and has some risk of bankruptcy.
When comparing the Altman-Z score of NAOV to the average industry Altman-Z score of 1.92, NAOV is less financially healthy than its industry peers. 92% of its industry peers have a better Altman-Z score.
The Piotroski-F score of NAOV is 2.00. This is a very weak score and indicates problems in health and profitability for NAOV.
VS Industry

Debt/Equity (0) VS Industry: 70% outperformed.

336.87
0.00

Quick Ratio (2) VS Industry: 37% outperformed.

0.06
33.20

Current Ratio (2.91) VS Industry: 39% outperformed.

0.12
33.20

Altman-Z (-15.76) VS Industry: 8% outperformed.

-101.74
76.52

Dividend

Dividend Rating

0

NAOV does not give a dividend.

NANOVIBRONIX INC0.3201

NASDAQ:NAOV (2/3/2023, 7:00:01 PM)-0.02 (-5.27%)

After market: 0.32 0 (-0.03%)

Chartmill FA Rating
GICS Sector Health Care
GICS IndustryGroup Health Care Equipment & Services
GICS Industry Health Care Equipment & Supplies
Earnings (Last) 11-14 2022-11-14/bmo Earnings (Next) N/A N/A
Inst Owners 4.5% Inst Owner Change 0%
Ins Owners 0.4% Ins Owner Change 38.17%
Market Cap 10.50M Analysts 82.86
Price Target N/A

Dividend
Industry RankSector Rank
Dividend Yield N/A
Dividend Growth(5Y) N/A DP N/A
Div Incr Years N/A Div Non Decr Years N/A
Ex-Date N/A

Surprises & Revisions
EPS beat(2) N/A Avg EPS beat(2) N/A
Min EPS beat(2) N/A Max EPS beat(2) N/A
EPS beat(4) N/A Avg EPS beat(4) N/A
Min EPS beat(4) N/A Max EPS beat(4) N/A
Revenue beat(2) N/A Avg Revenue beat(2) N/A
Min Revenue beat(2) N/A Max Revenue beat(2) N/A
Revenue beat(4) N/A Avg Revenue beat(4) N/A
Min Revenue beat(4) N/A Max Revenue beat(4) N/A
PT rev (1m) N/A PT rev (3m) N/A
EPS NQ rev (1m) N/A EPS NQ rev (3m) N/A
EPS NY rev (1m) N/A EPS NY rev (3m) N/A
Revenue NQ rev (1m) N/A Revenue NQ rev (3m) N/A
Revenue NY rev (1m) N/A Revenue NY rev (3m) N/A

Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 6.44
P/FCF N/A
P/OCF N/A
P/B 3.33
P/tB 3.33
EV/EBITDA N/A
EPS(TTM) -0.22 EY N/A
EPS(NY) N/A Fwd EY N/A
FCF(TTM) -0.2 FCFY N/A
OCF(TTM) -0.2 OCFY N/A
SpS 0.05 BVpS 0.1
TBVpS 0.1 PEG (NY) N/A
PEG (5Y) N/A

Profitability
Industry RankSector Rank
ROA N/A
ROE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM N/A
GM 44.44%
ROICexgc(3y) N/A ROICexcg growth 3Y N/A
ROICexcg growth 5Y N/A ROICexc(3y) N/A
ROICexc growth 3Y N/A ROICexc growth 5Y N/A
OM growth 3Y N/A OM growth 5Y N/A
PM growth 3Y N/A PM growth 5Y N/A
GM growth 3Y -3.15% GM growth 5Y -5.68%
F-Score 2 Asset Turnover 0.31

Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 200%
Profit Quality N/A
Current Ratio 2.91
Quick Ratio 2
Altman-Z -15.76
F-Score 2 WACC 8.78%
ROIC/WACC N/A Cap/Depr(3y) N/A
Cap/Depr(5y) N/A Profit Quality(3y) N/A
Profit Quality(5y) N/A

Growth
EPS 1Y 58.42% EPS 3Y N/A
EPS 5Y N/A EPS growth Q2Q 86.66%
EPS Next Y N/A EPS Next 2Y N/A
EPS Next 3Y N/A EPS Next 5Y N/A
Revenue growth 1Y 61.77% Revenue growth 3Y 74.32%
Revenue growth 5Y 49.1% Revenue growth Q2Q -80.56%
Revenue Next Year N/A Revenue Next 2Y N/A
Revenue Next 3Y N/A Revenue Next 5Y N/A
EBIT growth 1Y -23.47% EBIT growth 3Y N/A
EBIT growth 5Y N/A EBIT Next Year N/A
EBIT Next 3Y N/A EBIT Next 5Y N/A
FCF growth 1Y -111.97% FCF growth 3Y N/A
FCF growth 5Y N/A OCF growth 1Y -111.84%
OCF growth 3Y N/A OCF growth 5Y N/A

Fundamental Stock Screener Links

Screen Image

Fundamental Stock Screener

Find stocks with similar Fundamental rating on the USA

Screen Image

Best Fundamental Competitors Stock Screener

Find the competitors with the best fundamentals on the USA

Screen Image

Best Valuation Competitors Stock Screener

Find the competitors with the best valuation on the USA

Screen Image

Best Dividend Competitors Stock Screener

Find the competitors with the best dividend on the USA